Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Genitourinary tumours, non prostate

2282 - Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): results from a Phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC)


20 Oct 2018


Proffered paper session - Genitourinary tumours, non prostate


Cytotoxic Therapy;  Immunotherapy

Tumour Site

Renal Cell Cancer


Brian Rini


B.I. Rini1, M. Huseni2, M.B. Atkins3, D.F. McDermott4, T.B. Powles5, B. Escudier6, R. Banchereau7, L. Liu7, N. Leng8, J. Fan7, J. Doss7, S. Nalle7, S. Carroll7, S. Li8, C. Schiff7, M. Green7, R.J. Motzer9

Author affiliations

  • 1 Medical Oncology, Taussig Cancer Institute Cleveland Clinic, 44195 - Cleveland/US
  • 2 Oncology Biomarkers Development, Genentech, Inc., South San Francisco/US
  • 3 Oncology & Medicine, Lombardi Cancer Center Georgetown University, 20007 - Washington/US
  • 4 Heme/onc, Beth Israel Deaconess Medical Center, 2215 - Boston/US
  • 5 Queen Mary University Of London, Barts Cancer Institute and the Royal Free Hospital, EC1A 7BE - London/GB
  • 6 Medical Oncology Department, Gustave Roussy, 94805 - Villejuif/FR
  • 7 Oncology, Genentech, Inc., South San Francisco/US
  • 8 Biostatistics, Genentech, Inc., South San Francisco/US
  • 9 Medical Oncology, Memorial Sloan Kettering Cancer Center, 10065 - New York/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2282


Atezo + bev demonstrated improved PFS vs sun in pts with untreated mRCC expressing PD-L1 in Ph II (IMmotion150) and Ph III studies. Biomarker analyses in IMmotion150 suggested that T effector/IFNγ (Teff) and Angiogenesis (Angio) gene expression signatures (GEs) were associated with differential outcomes with atezo + bev and sun. We conducted genomic analyses to validate these GEs with clinical outcomes in IMmotion151 and evaluated their association with MSKCC risk groups and sarcomatoid histology.


Tumour GE analysis was performed by RNASeq in 823 pts from IMmotion151. Associations of Teff and Angio GEs with clinical outcome were evaluated at pre-specified expression level cutoffs identified in IMmotion150. PD-L1 status on immune cells was assessed with the SP142 IHC assay.


IMmotion151 met its co-primary endpoint, demonstrating improved PFS with atezo + bev vs sun in PD-L1+ pts (HR, 0.74 [95% CI: 0.57-0.96]; P = 0.02) across MSKCC groups. PFS was also improved in pts with sarcomatoid histology (HR, 0.56 [95% CI: 0.38-0.83]). High Teff GE was associated with PD-L1 expression by IHC and longer PFS in atezo + bev vs sun pts (HR, 0.76 [95% CI: 0.59-0.99]). High Angio GE was associated with improved PFS in the sun arm (HR, 0.59 [95% CI: 0.47-0.75]) but did not differentiate clinical activity between atezo + bev vs sun (HR, 0.95 [95% CI: 0.75-1.19]). Atezo + bev improved PFS vs sun in the low Angio subset (HR, 0.68 [95% CI: 0.52-0.89]). Angio GE was higher (P=4.28e-06) in favourable vs intermediate/poor MSKCC risk groups. PD-L1+ prevalence was higher (63% vs 39%) and Angio GE was lower (P=4.73e-16) in sarcomatoid vs non-sarcomatoid tumours.


These prospectively tested biomarker results validate molecular signatures that differentiate clinical outcomes with VEGF inhibition and immunotherapy in 1L mRCC. Moreover, these data identify tumour genomic profiles associated with prognostic risk groups and sarcomatoid histology. Findings from this study further our understanding of the biology of kidney cancer and inform future strategies to enable personalized therapy in mRCC pts.

Clinical trial identification


Editorial Acknowledgement

Medical writing assistance for this abstract was provided by Paige S. Davies, PhD, of Health Interactions.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.